Astrazeneca Shs Sponsored American Deposit Receipt Repr 1 Sh $63.49

down -0.04


17/4/2014 06:40 PM  |  NYSE : AZN  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get AZN Trend Analysis - it has outperformed the S&P 500 by 5%

Partner Headlines

  1. Myriad, Tata Motors Among RS Leaders In Correction

    IBD
  2. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  3. Abbott Capturing Incremental Market Share

    GuruFocus
  4. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  5. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  6. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  7. AstraZeneca hurt by generics

    IBD
  8. AstraZeneca Q4 Mixed, But Alzheimer's Drug Advances

    IBD
  9. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  10. Market Wrap For January 22: Earnings Season Continues To Come In Mixed

    Benzinga
  11. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  12. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  13. Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

    Benzinga
  14. Stocks Hitting 52-Week Highs

    Benzinga
  15. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  16. ObamaCare = Drug Maker Assistance Act

    YCharts
  17. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  18. Benzinga's Top Downgrades

    Benzinga
  19. AstraZeneca in $4 bil-plus buy

    IBD
  20. Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus

    IBD
  21. Market Wrap For December 18: Markets Flat During Day One Post Fed Taper

    Benzinga
  22. Bristol-Myers Dumping Disaster Onto AstraZeneca?

    YCharts
  23. AstraZeneca Buys Out Bristol-Myers' Diabetes Business

    IBD
  24. AstraZeneca to Buy Bristol's Stake in Joint Venture

    FoxBusiness
  25. Cubist drug passes 2nd test

    IBD
  26. Suppose Medicare Negotiated Like This?

    YCharts
  27. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  28. Cubist Antibiotic Passes Second Test; FDA Filing Next

    IBD
  29. Bristol, AstraZeneca pull drug

    IBD
  30. Genpact, AstraZeneca Extend Finance and Accounting Services Agreement

    Benzinga
  31. Health Care Heartiest, Gold Funds All Red In November

    IBD
  32. Icahn stake boosts Hologic

    IBD
  33. Icahn's Buy Into Hologic Welcomed By Wall Street

    IBD
  34. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga
  35. Benzinga's Top Upgrades

    Benzinga
  36. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  37. Statin Rules Change: Does Pharma Have A Winner?

    YCharts
  38. List: $34B In Pharma Sales Lose Patent in 2014

    YCharts
  39. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  40. Two Mega-Launches in Pharma Industry

    YCharts
  41. AstraZeneca Appoints New CFO as Profit Falls

    FoxBusiness
  42. Benzinga's Top Upgrades

    Benzinga
  43. Acacia Subsidiary Enters into Settlement Agreement with AstraZeneca

    Benzinga
  44. AstraZeneca Reports New Safety Data for Naloxegol, Says Most Naloxegol-Emergent ...

    Benzinga
  45. How Much Do Analysts Hype Drug Launches?

    YCharts
  46. Profits Are Good, Cures Are Better: The Pharmaceutical Industry

    GuruFocus
  47. Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV

    Benzinga
  48. 4 High-Yielding Stocks with Safe Haven Characteristics and 9 Additional ...

    GuruFocus
  49. Pharma's Cheerleaders: Drug Reps' Jobs At Risk

    YCharts
  50. AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin ...

    Benzinga
Trading Center